» Articles » PMID: 29038604

Overexpression of OSM and IL-6 Impacts the Polarization of Pro-fibrotic Macrophages and the Development of Bleomycin-induced Lung Fibrosis

Overview
Journal Sci Rep
Specialty Science
Date 2017 Oct 18
PMID 29038604
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Although recent evidence indicates that gp130 cytokines, Oncostatin M (OSM) and IL-6 are involved in alternative programming of macrophages, their role in lung fibrogenesis is poorly understood. Here, we investigated the effect of transient adenoviral overexpression of OSM or IL-6 in mice during bleomycin-induced lung fibrosis. Lung fibrosis and M2-like macrophage accumulation were assessed by immunohistochemistry, western blotting, gene expression and flow cytometry. Ex-vivo isolated alveolar and bone marrow-derived macrophages were examined for M2-like programming and signalling. Airway physiology measurements at day 21 demonstrated that overexpression of OSM or IL-6 exacerbated bleomycin-induced lung elastance, consistent with histopathological assessment of extracellular matrix and myofibroblast accumulation. Flow cytometry analysis at day 7 showed increased numbers of M2-like macrophages in lungs of mice exposed to bleomycin and OSM or IL-6. These macrophages expressed the IL-6Rα, but were deficient for OSMRβ, suggesting that IL-6, but not OSM, may directly induce alternative macrophage activation. In conclusion, the gp130 cytokines IL-6 and OSM contribute to the accumulation of profibrotic macrophages and enhancement of bleomycin-induced lung fibrosis. This study suggests that therapeutic strategies targeting these cytokines or their receptors may be beneficial to prevent the accumulation of M2-like macrophages and the progression of fibrotic lung disease.

Citing Articles

Advances in Interleukin-6 Family Cytokines and the Role in Respiratory Diseases.

Ji T, Huang G, Cao Y, Gao Y, Gao X J Inflamm Res. 2025; 18:3125-3141.

PMID: 40059944 PMC: 11889408. DOI: 10.2147/JIR.S508031.


Fibroblasts in heterotopic ossification: mechanisms and therapeutic targets.

Li J, Dang Y, Liu M, Gao L, Lin H Int J Biol Sci. 2025; 21(2):544-564.

PMID: 39781450 PMC: 11705629. DOI: 10.7150/ijbs.102297.


Development of immunocompetent full thickness skin tissue constructs to model skin fibrosis for high-throughput drug screening.

Lim Y, Quinn R, Bharti K, Ferrer M, Zarkoob H, Song M Biofabrication. 2024; 17(1).

PMID: 39622178 PMC: 11638742. DOI: 10.1088/1758-5090/ad998c.


Increased serum level of IL-6 predicts poor prognosis in anti-MDA5-positive dermatomyositis with rapidly progressive interstitial lung disease.

Niu Y, Liu S, Qiu Q, Fu D, Xiao Y, Liang L Arthritis Res Ther. 2024; 26(1):184.

PMID: 39468670 PMC: 11520069. DOI: 10.1186/s13075-024-03415-5.


Direct M2 macrophage co-culture overrides viscoelastic hydrogel mechanics to promote fibroblast activation.

Astrab L, Skelton M, Caliari S bioRxiv. 2024; .

PMID: 39463963 PMC: 11507682. DOI: 10.1101/2024.10.13.618034.


References
1.
West N, Hegazy A, Owens B, Bullers S, Linggi B, Buonocore S . Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017; 23(5):579-589. PMC: 5420447. DOI: 10.1038/nm.4307. View

2.
Rennard S, Hunninghake G, Bitterman P, Crystal R . Production of fibronectin by the human alveolar macrophage: mechanism for the recruitment of fibroblasts to sites of tissue injury in interstitial lung diseases. Proc Natl Acad Sci U S A. 1981; 78(11):7147-51. PMC: 349213. DOI: 10.1073/pnas.78.11.7147. View

3.
Komori T, Tanaka M, Furuta H, Akamizu T, Miyajima A, Morikawa Y . Oncostatin M is a potential agent for the treatment of obesity and related metabolic disorders: a study in mice. Diabetologia. 2015; 58(8):1868-76. DOI: 10.1007/s00125-015-3613-9. View

4.
Pesce J, Ramalingam T, Mentink-Kane M, Wilson M, El Kasmi K, Smith A . Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog. 2009; 5(4):e1000371. PMC: 2660425. DOI: 10.1371/journal.ppat.1000371. View

5.
Sester D, Thygesen S, Sagulenko V, Vajjhala P, Cridland J, Vitak N . A novel flow cytometric method to assess inflammasome formation. J Immunol. 2014; 194(1):455-62. DOI: 10.4049/jimmunol.1401110. View